Navigation Links
Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
Date:10/22/2008

SAN DIEGO, Oct. 22 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the BIOCOM Investor Conference on October 28, 2008 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) at the Hyatt Regency Hotel in La Jolla, California. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide an overview of the company, including its clinical development and discovery programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Stateme
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
4. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
5. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
6. ThreeWire Expands Presence in the Pharmaceutical Arena
7. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
8. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
9. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
11. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com announces ... in its catalogue: Global Chelating Agents ... About Chelating Agent A chelating agent ... bonds with metal ions, thereby forming a metal-ion ... metal-ions have on chemical processes, formulations, and the ...
(Date:8/27/2014)... 27, 2014  A novel biomarker for rheumatoid ... better identify early-stage disease, when treatment can often ... a new study in The Journal of Rheumatology. ... DGX ) and other institutions found that ... conventional antibody-serum testing, including rheumatoid factor (RF) and ...
(Date:8/27/2014)... LONDON , Aug. 27, 2014 ... The Graphene Opportunity - A Rational ... Is Graphene The New Nanotech? A similar ... predictions of applications ranging from microelectronics to water ... today announced the availability of the Graphene Opportunity ...
(Date:8/27/2014)... -- Research and Markets  has announced the addition ... Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... mass spectrometer industry. The report provides a ... and industry chain structure. The isotope ratio mass spectrometer ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2
... /Xinhua-PRNewswire-FirstCall/ -- American Oriental,Bioengineering, Inc. (NYSE: AOB ... quarter 2008 financial results on Monday, November 10, ... hold a conference call at 8:00 am ET ... 2008 results. Listeners may access the,call by dialing ...
... 30 /PRNewswire-FirstCall/,-- Oridion Systems Ltd. (SWX: ORIDN) ... Foundation Health Plan, Inc., America,s largest,non-profit health ... in the world. The agreement is for ... sampling consumables (FilterLine(R))., With this agreement, ...
... ... Guidance of $0.90 - $1.10 for 2009 and $1.50 - $1.70 ... for 2010, PITTSBURGH, Oct. 30 ... months ended,Sept. 30, 2008., Financial Highlights, -- Adjusted diluted EPS of $0.23 and $0.52 ...
Cached Biology Technology:Oridion Signs Agreement With Major US Health Plan Provider for Microstream(R) Capnography 2Oridion Signs Agreement With Major US Health Plan Provider for Microstream(R) Capnography 3Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 2Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 3Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 4Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 5Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 6Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 7Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 8Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 9Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 10Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 11Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 12Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 13Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 14
(Date:8/27/2014)... of consumers are willing to pay a premium for ... they,re getting what the label claims is another matter. ... a new way to make sure farms are labelling ... Journal of Agricultural and Food Chemistry , could ... Bavarian Health and Food Safety Authority and the Wuerzburg ...
(Date:8/27/2014)... studies have shown that excessive iron is ... disease. Previous studies from Chunyan Guo and ... have shown that baicalin prevented iron accumulation ... transporter 1 expression, and increased ferroportin 1 ... Parkinson,s disease rats. However, the relationship between ...
(Date:8/27/2014)... are greedy bird-brains, University of Warwick research finds ... they make risky decisions, new research has shown. , ... of Warwick,s Department of Psychology, conducted tests that found ... likely to gamble for high-value than low-value rewards. , ... that the test results show the important role that ...
Breaking Biology News(10 mins):Gamblers are greedy bird-brains, University of Warwick research finds 2
... and the U.S.A., the scientists have shown how cutting-edge ... of active proteins in cell organelles at a particular ... use proteins. The work is published in the journal ... cities. They contain all the necessary parts that allow ...
... the use of liquid crystalline polymers (LCP) as a ... sought-after lab-on-a-chip technology. , University of Alberta researchers, collaborating ... Phillips Research Laboratories in the Netherlands, have shown that ... glass backing, can be fabricated and patterned on a ...
... of dengue fever wax and wane over a period ... why. With the incidence and range of the potentially ... these epidemics has never been more important. , A ... suggests that a brief period of cross-immunity conferred by ...
Cached Biology News:A catalogue of proteins 2Polymers show promise for lab-on-a-chip technology 2UGA study explains peaks and troughs of dengue epidemics 2UGA study explains peaks and troughs of dengue epidemics 3
Request Info...
Request Info...
Detect and measure levels of mouse IgG2b antibody isotypes quickly and easily....
Detect and measure levels of mouse IgG3 antibody isotypes quickly and easily....
Biology Products: